ARDX Quote, Financials, Valuation and Earnings

Fate Therapeutics, Inc. has a net margin of -0.88% compared to Ardelyx, Inc.'s net margin of -1852.38%. Ardelyx, Inc.'s return on equity of -36.67% beat Fate Therapeutics, Inc.'s return on equity of -53.28%.

Ardelyx, Inc. has a consensus price target of $14.70, signalling upside risk potential of 118.75%. On the other hand Fate Therapeutics, Inc. has an analysts' consensus of $4.94 which suggests that it could grow by 260.91%. Given that Fate Therapeutics, Inc. has higher upside potential than Ardelyx, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Ardelyx, Inc..

Ardelyx, Inc. has a beta of 0.570, which suggesting that the stock is 43.011% less volatile than S&P 500. In comparison Fate Therapeutics, Inc. has a beta of 2.246, suggesting its more volatile than the S&P 500 by 124.561%.

Ardelyx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fate Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx, Inc. pays -- of its earnings as a dividend. Fate Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ardelyx, Inc. quarterly revenues are $110.3M, which are larger than Fate Therapeutics, Inc. quarterly revenues of $1.7M. Ardelyx, Inc.'s net income of -$969K is higher than Fate Therapeutics, Inc.'s net income of -$32.3M. Notably, Ardelyx, Inc.'s price-to-earnings ratio is -- while Fate Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx, Inc. is 4.07x versus 22.73x for Fate Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -0.88% compared to Ardelyx, Inc.'s net margin of -82.06%. Ardelyx, Inc.'s return on equity of -36.67% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ardelyx, Inc. has a consensus price target of $14.70, signalling upside risk potential of 118.75%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 10.83%. Given that Ardelyx, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ardelyx, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ardelyx, Inc. has a beta of 0.570, which suggesting that the stock is 43.011% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Ardelyx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ardelyx, Inc. quarterly revenues are $110.3M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ardelyx, Inc.'s net income of -$969K is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ardelyx, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx, Inc. is 4.07x versus 14.00x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -0.88% compared to Ardelyx, Inc.'s net margin of 9.72%. Ardelyx, Inc.'s return on equity of -36.67% beat MannKind Corp.'s return on equity of --.

Ardelyx, Inc. has a consensus price target of $14.70, signalling upside risk potential of 118.75%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 76.68%. Given that Ardelyx, Inc. has higher upside potential than MannKind Corp., analysts believe Ardelyx, Inc. is more attractive than MannKind Corp..

Ardelyx, Inc. has a beta of 0.570, which suggesting that the stock is 43.011% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.

Ardelyx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Ardelyx, Inc. quarterly revenues are $110.3M, which are larger than MannKind Corp. quarterly revenues of $82.1M. Ardelyx, Inc.'s net income of -$969K is lower than MannKind Corp.'s net income of $8M. Notably, Ardelyx, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 57.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx, Inc. is 4.07x versus 5.35x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -0.88% compared to Ardelyx, Inc.'s net margin of 36.91%. Ardelyx, Inc.'s return on equity of -36.67% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Ardelyx, Inc. has a consensus price target of $14.70, signalling upside risk potential of 118.75%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $529.96 which suggests that it could grow by 10.89%. Given that Ardelyx, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ardelyx, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ardelyx, Inc. has a beta of 0.570, which suggesting that the stock is 43.011% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Ardelyx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ardelyx, Inc. quarterly revenues are $110.3M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Ardelyx, Inc.'s net income of -$969K is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Ardelyx, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx, Inc. is 4.07x versus 10.20x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.